Primary percutaneous coronary intervention in acute ST-elevation myocardial infarction: Non-culprit lesions
- J Dawn Abbott, MD, FACC
J Dawn Abbott, MD, FACC
- Associate Professor of Medicine
- Brown Medical School
- Paul Sorajja, MD
Paul Sorajja, MD
- Director, Center for Valve and Structural Heart Disease
- Minneapolis Heart Institute
Coronary artery reperfusion with primary percutaneous coronary intervention, compared with either no reperfusion therapy or fibrinolysis, improves outcomes in patients with acute ST-elevation myocardial infarction (STEMI) if performed in a timely fashion. (See "Acute ST elevation myocardial infarction: Selecting a reperfusion strategy", section on 'Summary and recommendations'.)
Usually, the lesion responsible for the infarct, often referred to as the “culprit lesion,” is readily identified and an attempt is made to re-establish blood flow with the use of thrombectomy, balloon angioplasty, or placement of one or more stents. (See "Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management".)
In addition to the culprit lesion(s), about 50 percent of STEMI patients have one or more obstructive lesions remote from the area of infarction (ie, "non-culprit" lesions). This topic will address the management of non-culprit lesions in patients with STEMI.
For patients with ST-elevation myocardial infarction who have been referred for primary percutaneous coronary intervention (PCI) and who have had non-culprit lesions identified, we use the following sequential approach:
●We perform primary PCI of the culprit lesion.To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:
- Vlaar PJ, Mahmoud KD, Holmes DR Jr, et al. Culprit vessel only versus multivessel and staged percutaneous coronary intervention for multivessel disease in patients presenting with ST-segment elevation myocardial infarction: a pairwise and network meta-analysis. J Am Coll Cardiol 2011; 58:692.
- Cardarelli F, Bellasi A, Ou FS, et al. Combined impact of age and estimated glomerular filtration rate on in-hospital mortality after percutaneous coronary intervention for acute myocardial infarction (from the American College of Cardiology National Cardiovascular Data Registry). Am J Cardiol 2009; 103:766.
- Rasoul S, Ottervanger JP, de Boer MJ, et al. Predictors of 30-day and 1-year mortality after primary percutaneous coronary intervention for ST-elevation myocardial infarction. Coron Artery Dis 2009; 20:415.
- Park DW, Clare RM, Schulte PJ, et al. Extent, location, and clinical significance of non-infarct-related coronary artery disease among patients with ST-elevation myocardial infarction. JAMA 2014; 312:2019.
- Halkin A, Singh M, Nikolsky E, et al. Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. J Am Coll Cardiol 2005; 45:1397.
- Sorajja P, Gersh BJ, Cox DA, et al. Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Eur Heart J 2007; 28:1709.
- Iqbal MB, Ilsley C, Kabir T, et al. Culprit vessel versus multivessel intervention at the time of primary percutaneous coronary intervention in patients with ST-segment-elevation myocardial infarction and multivessel disease: real-world analysis of 3984 patients in London. Circ Cardiovasc Qual Outcomes 2014; 7:936.
- Bainey KR, Mehta SR, Lai T, Welsh RC. Complete vs culprit-only revascularization for patients with multivessel disease undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a systematic review and meta-analysis. Am Heart J 2014; 167:1.
- Wald DS, Morris JK, Wald NJ, et al. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med 2013; 369:1115.
- Gershlick AH, Khan JN, Kelly DJ, et al. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial. J Am Coll Cardiol 2015; 65:963.
- Smits PC, Abdel-Wahab M, Neumann FJ, et al. Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction. N Engl J Med 2017; 376:1234.
- Elgendy IY, Mahmoud AN, Kumbhani DJ, et al. Complete or Culprit-Only Revascularization for Patients With Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Pairwise and Network Meta-Analysis of Randomized Trials. JACC Cardiovasc Interv 2017; 10:315.
- Politi L, Sgura F, Rossi R, et al. A randomised trial of target-vessel versus multi-vessel revascularisation in ST-elevation myocardial infarction: major adverse cardiac events during long-term follow-up. Heart 2010; 96:662.
- Dönmez E, Koç M, Şeker T, et al. The assessment of non culprit coronary artery lesions in patients with ST segment elevated myocardial infarction and multivessel disease by control angiography with quantitative coronary angiography. Int J Cardiovasc Imaging 2016; 32:1471.
- Thim T, Egholm G, Olesen KK, et al. Staged re-evaluation of non-culprit lesions in ST segment elevation myocardial infarction: a retrospective study. Open Heart 2016; 3:e000427.
- van der Schaaf RJ, Claessen BE, Vis MM, et al. Effect of multivessel coronary disease with or without concurrent chronic total occlusion on one-year mortality in patients treated with primary percutaneous coronary intervention for cardiogenic shock. Am J Cardiol 2010; 105:955.
- Claessen BE, Dangas GD, Weisz G, et al. Prognostic impact of a chronic total occlusion in a non-infarct-related artery in patients with ST-segment elevation myocardial infarction: 3-year results from the HORIZONS-AMI trial. Eur Heart J 2012; 33:768.
- Christakopoulos GE, Christopoulos G, Carlino M, et al. Meta-analysis of clinical outcomes of patients who underwent percutaneous coronary interventions for chronic total occlusions. Am J Cardiol 2015; 115:1367.
- Henriques JP, Hoebers LP, Råmunddal T, et al. Percutaneous Intervention for Concurrent Chronic Total Occlusions in Patients With STEMI: The EXPLORE Trial. J Am Coll Cardiol 2016; 68:1622.
- O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:e362.
- Levine GN, Bates ER, Blankenship JC, et al. 2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. J Am Coll Cardiol 2016; 67:1235.
- Authors/Task Force members, Windecker S, Kolh P, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35:2541.
- OUR APPROACH
- IMPACT OF NON-CULPRIT LESIONS
- MANAGEMENT APPROACHES TO NON-CULPRIT LESIONS
- UNANSWERED QUESTIONS
- What is the optimal timing?
- Which non-culprit lesions?
- - Chronic total occlusions
- Who should receive FFR
- RECOMMENDATIONS OF OTHERS
- SOCIETY GUIDELINE LINKS
- SUMMARY AND RECOMMENDATIONS